Merck’s Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.
Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...
STAT1d
Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded
Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in ...
FiercePharma1d
Taking its best shot at Roche, Merck scores in phase 3 trial of subcutaneous Keytruda
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
pharmaphorum6h
MSD says subcutaneous Keytruda matches IV form
The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...
BioSpace1d
Merck’s Subcutaneous Keytruda Meets Expectations in Phase III
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...
Merck's Phase 3 Study Of Subcutaneous Keytruda To Treat NSCLC Meets Primary Goals
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
devdiscourse1h
Global Health Updates: Emerging Vaccines, Legal Rulings, and Sector Insights
Recent health news highlights include WHO's emergency listing of a mpox vaccine, Pfizer's legal setback in recouping ...
clinicaltrialsarena4h
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...